DE2656317C2 - Verfahren zur Herstellung einer Suspension von beladenen Erythrocyten - Google Patents

Verfahren zur Herstellung einer Suspension von beladenen Erythrocyten

Info

Publication number
DE2656317C2
DE2656317C2 DE2656317A DE2656317A DE2656317C2 DE 2656317 C2 DE2656317 C2 DE 2656317C2 DE 2656317 A DE2656317 A DE 2656317A DE 2656317 A DE2656317 A DE 2656317A DE 2656317 C2 DE2656317 C2 DE 2656317C2
Authority
DE
Germany
Prior art keywords
solution
membrane
cell
cells
membrane vesicles
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
DE2656317A
Other languages
German (de)
English (en)
Other versions
DE2656317A1 (de
Inventor
Günter Dr. Pilwat
Ulrich Prof. Dr. 5170 Jülich Zimmermann
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Forschungszentrum Juelich GmbH
Original Assignee
Kernforschungsanlage Juelich GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kernforschungsanlage Juelich GmbH filed Critical Kernforschungsanlage Juelich GmbH
Priority to DE2656317A priority Critical patent/DE2656317C2/de
Priority to CH1378777A priority patent/CH632412A5/de
Priority to FR7737046A priority patent/FR2373290A1/fr
Priority to SE7713945A priority patent/SE445423B/sv
Priority to JP14776577A priority patent/JPS5396382A/ja
Priority to US05/859,563 priority patent/US4269826A/en
Priority to GB51534/77A priority patent/GB1560166A/en
Priority to IL53595A priority patent/IL53595A/xx
Publication of DE2656317A1 publication Critical patent/DE2656317A1/de
Application granted granted Critical
Publication of DE2656317C2 publication Critical patent/DE2656317C2/de
Expired legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/18—Erythrocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5063—Compounds of unknown constitution, e.g. material from plants or animals
    • A61K9/5068—Cell membranes or bacterial membranes enclosing drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5094—Microcapsules containing magnetic carrier material, e.g. ferrite for drug targeting

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • Biotechnology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Botany (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
  • Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
  • Medicinal Preparation (AREA)
DE2656317A 1976-12-11 1976-12-11 Verfahren zur Herstellung einer Suspension von beladenen Erythrocyten Expired DE2656317C2 (de)

Priority Applications (8)

Application Number Priority Date Filing Date Title
DE2656317A DE2656317C2 (de) 1976-12-11 1976-12-11 Verfahren zur Herstellung einer Suspension von beladenen Erythrocyten
CH1378777A CH632412A5 (de) 1976-12-11 1977-11-11 Verfahren zur herstellung einer masse von in einer physiologischen loesung suspendierten beladenen zellen.
SE7713945A SE445423B (sv) 1976-12-11 1977-12-08 Forfarande for framstellning av en suspension av i fysiologisk losning suspenderade och med metotrexat eller 6-fluorouracil belastade blodceller samt magnetiska substanser
FR7737046A FR2373290A1 (fr) 1976-12-11 1977-12-08 Procede pour la preparation d'une masse de cellules chargees en suspension dans une solution physiologique
JP14776577A JPS5396382A (en) 1976-12-11 1977-12-10 Production of assembled substance of load cell suspended in phisiological solution
US05/859,563 US4269826A (en) 1976-12-11 1977-12-12 Physiological preparation containing loaded cells in suspension and a magnetic agent for local concentration thereof in a living body
GB51534/77A GB1560166A (en) 1976-12-11 1977-12-12 Loaded cells
IL53595A IL53595A (en) 1976-12-11 1977-12-13 Biological cells comprising pharmaceutically active substances and particles of magnetic material,their preparation and pharmaceutical compositions containing them

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE2656317A DE2656317C2 (de) 1976-12-11 1976-12-11 Verfahren zur Herstellung einer Suspension von beladenen Erythrocyten

Publications (2)

Publication Number Publication Date
DE2656317A1 DE2656317A1 (de) 1978-06-22
DE2656317C2 true DE2656317C2 (de) 1986-06-19

Family

ID=5995351

Family Applications (1)

Application Number Title Priority Date Filing Date
DE2656317A Expired DE2656317C2 (de) 1976-12-11 1976-12-11 Verfahren zur Herstellung einer Suspension von beladenen Erythrocyten

Country Status (8)

Country Link
US (1) US4269826A (cg-RX-API-DMAC7.html)
JP (1) JPS5396382A (cg-RX-API-DMAC7.html)
CH (1) CH632412A5 (cg-RX-API-DMAC7.html)
DE (1) DE2656317C2 (cg-RX-API-DMAC7.html)
FR (1) FR2373290A1 (cg-RX-API-DMAC7.html)
GB (1) GB1560166A (cg-RX-API-DMAC7.html)
IL (1) IL53595A (cg-RX-API-DMAC7.html)
SE (1) SE445423B (cg-RX-API-DMAC7.html)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3925680A1 (de) * 1989-08-03 1991-02-07 Kruess Gmbh Wissenschaftliche Verfahren zur herstellung vitaler wirkstoff-beladener humanerythrozyten
DE102004054536A1 (de) * 2004-11-06 2006-05-11 Capsulution Nanoscience Ag Multimodal veränderte Zellen als zellulare Darreichungsformen für aktive Substanzen und als diagnostische Zellpartikel

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4345588A (en) * 1979-04-23 1982-08-24 Northwestern University Method of delivering a therapeutic agent to a target capillary bed
JPS5661992A (en) * 1979-10-24 1981-05-27 Kibun Kk Fermentation and/or aging method
US4331654A (en) 1980-06-13 1982-05-25 Eli Lilly And Company Magnetically-localizable, biodegradable lipid microspheres
US4392040A (en) * 1981-01-09 1983-07-05 Rand Robert W Induction heating apparatus for use in causing necrosis of neoplasm
US4558690A (en) * 1982-01-26 1985-12-17 University Of Scranton Method of administration of chemotherapy to tumors
FR2529463B1 (fr) * 1982-07-05 1986-01-10 Centre Nat Rech Scient Procede et dispositif pour l'encapsulation dans les erythrocytes d'au moins une substance a activite biologique, notamment des effecteurs allosteriques de l'hemoglobine et erythrocytes ainsi obtenus
US4731239A (en) * 1983-01-10 1988-03-15 Gordon Robert T Method for enhancing NMR imaging; and diagnostic use
US4622952A (en) * 1983-01-13 1986-11-18 Gordon Robert T Cancer treatment method
US4545368A (en) * 1983-04-13 1985-10-08 Rand Robert W Induction heating method for use in causing necrosis of neoplasm
US4590922A (en) * 1983-08-19 1986-05-27 Gordon Robert T Use of ferromagnetic, paramagnetic and diamagnetic particles in the treatment of infectious diseases
US4829984A (en) * 1983-12-15 1989-05-16 Gordon Robert T Method for the improvement of transplantation techniques and for the preservation of tissue
US4610241A (en) * 1984-07-03 1986-09-09 Gordon Robert T Atherosclerosis treatment method
US4652257A (en) * 1985-03-21 1987-03-24 The United States Of America As Represented By The Secretary Of The Navy Magnetically-localizable, polymerized lipid vesicles and method of disrupting same
US4983159A (en) * 1985-03-25 1991-01-08 Rand Robert W Inductive heating process for use in causing necrosis of neoplasms at selective frequencies
US4690130A (en) * 1985-12-19 1987-09-01 Mirell Stuart G Electromagnetic therapy control system
US5019372A (en) * 1986-06-27 1991-05-28 The Children's Medical Center Corporation Magnetically modulated polymeric drug release system
US4770183A (en) * 1986-07-03 1988-09-13 Advanced Magnetics Incorporated Biologically degradable superparamagnetic particles for use as nuclear magnetic resonance imaging agents
US4950221A (en) * 1986-07-18 1990-08-21 Gordon Robert T Process for affecting molecules in tissue
US4996991A (en) * 1986-07-18 1991-03-05 Gordon Robert T Method for following the distribution of particles in neurological or neuromuscular tissue and cells
US4923437A (en) * 1986-07-18 1990-05-08 Gordon Robert T Process for applying a localized magnetic or electric field
US4869247A (en) * 1988-03-11 1989-09-26 The University Of Virginia Alumni Patents Foundation Video tumor fighting system
US5057301A (en) * 1988-04-06 1991-10-15 Neorx Corporation Modified cellular substrates used as linkers for increased cell retention of diagnostic and therapeutic agents
US4935223A (en) * 1988-08-04 1990-06-19 Board Of Regents, The University Of Texas System Labeled cells for use in imaging
EP0487615B1 (en) * 1989-08-18 1994-01-05 Monsanto Company Ferritin analogs
SU1722256A3 (ru) * 1989-11-02 1992-03-23 Viktor A Volkonskij Cпocoб пoлучehия maгhиtoупpabляemoй диcпepcии
US5125888A (en) * 1990-01-10 1992-06-30 University Of Virginia Alumni Patents Foundation Magnetic stereotactic system for treatment delivery
US5443813A (en) * 1991-06-06 1995-08-22 Associated Universities, Inc. Loading and conjugating cavity biostructures
US6374670B1 (en) * 1995-03-13 2002-04-23 University Of Washington Non-invasive gut motility monitor
AU6639596A (en) 1995-07-28 1997-02-26 James R. Gray Use of a polarizing field to modify the efficacy of a bioactive agent
US20060003163A1 (en) * 1996-11-16 2006-01-05 Nanomagnetics Limited Magnetic fluid
US6986942B1 (en) 1996-11-16 2006-01-17 Nanomagnetics Limited Microwave absorbing structure
US6815063B1 (en) 1996-11-16 2004-11-09 Nanomagnetics, Ltd. Magnetic fluid
US6713173B2 (en) 1996-11-16 2004-03-30 Nanomagnetics Limited Magnetizable device
GB2319253A (en) 1996-11-16 1998-05-20 Eric Leigh Mayes Composition, for use in a device, comprising a magnetic layer of domain-separated magnetic particles
EP0882448B1 (en) * 1997-05-05 2005-01-12 DIDECO S.r.l. Method of encapsulating biologically active agents within erythrocytes and apparatus therefor
US6135118A (en) * 1997-05-12 2000-10-24 Dailey; James P. Treatment with magnetic fluids
US6203487B1 (en) * 1997-12-31 2001-03-20 Thomas Jefferson University Use of magnetic particles in the focal delivery of cells
WO2000006244A2 (en) 1998-07-30 2000-02-10 Hainfeld James F Loading metal particles into cell membrane vesicles and metal particle use for imaging and therapy
US20060041182A1 (en) * 2003-04-16 2006-02-23 Forbes Zachary G Magnetically-controllable delivery system for therapeutic agents
US6972095B1 (en) 2003-05-07 2005-12-06 Electric Power Research Institute Magnetic molecules: a process utilizing functionalized magnetic ferritins for the selective removal of contaminants from solution by magnetic filtration
US8986736B2 (en) * 2003-06-24 2015-03-24 Baxter International Inc. Method for delivering particulate drugs to tissues
US9044381B2 (en) * 2003-06-24 2015-06-02 Baxter International Inc. Method for delivering drugs to the brain
EP1713443A2 (en) * 2004-01-29 2006-10-25 Baxter International Inc. Nanosuspensions of anti-retroviral agents for increased central nervous system delivery
US20070100457A1 (en) * 2004-03-04 2007-05-03 Hyde Edward R Jr Paramagnetic liquid interface
KR20070037444A (ko) * 2004-06-15 2007-04-04 백스터 인터내셔널 인코포레이티드 고체 미립자성 치료제의 생체외 적용방법
EP1849482A1 (en) * 2006-04-25 2007-10-31 Capsulution Nanoscience AG Multimodally altered cells as a form for administering active substances and as diagnostic particles
US20080097606A1 (en) * 2006-10-19 2008-04-24 Cragg Andrew H Knee joint prosthesis and hyaluronate compositions for treatment of osteoarthritis
GB0621894D0 (en) * 2006-11-02 2006-12-13 Iti Scotland Ltd Magnetic recognition system
EP2259798B1 (en) 2008-03-05 2013-12-11 Baxter International Inc. Surface-modified particles and methods for targeted drug delivery
GB0808090D0 (en) * 2008-05-02 2008-06-11 Iti Scotland Ltd Use of magnetic proteins in medicine
US10952965B2 (en) * 2009-05-15 2021-03-23 Baxter International Inc. Compositions and methods for drug delivery
US20120061317A1 (en) * 2010-09-13 2012-03-15 Beng Joo Reginald Thio Magnetic Pollen Grains as Sorbents for Organic Pollutants in Aqueous Media

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3474777A (en) * 1966-02-10 1969-10-28 Amp Inc Method of administering therapeutic agents
US3700555A (en) * 1970-10-12 1972-10-24 Technicon Instr Method and apparatus for lymphocyte separation from blood
US3709791A (en) * 1971-04-13 1973-01-09 Technicon Instr Method and apparatus for lymphocyte separation from blood
US3887698A (en) * 1973-03-12 1975-06-03 Univ Leland Stanford Junior Sacs with epitopic sites on walls enclosing stable free radicals
DE2326224C3 (de) 1973-05-23 1975-11-13 Kernforschungsanlage Juelich Gmbh, 5170 Juelich Verfahren zum Abtrenne», von durch chemische oder physikalisch^ Eigenschaften ausgezeichneten ionisierten Stoffen aus einer wäßrigen Lösung
DE2326191B2 (de) 1973-05-23 1978-03-30 Hutschenreuther Ag, 8672 Selb Verfahren zum Herstellen eines Reliefdekors auf keramischen Erzeugnissen
DE2326161C2 (de) 1973-05-23 1986-07-17 Kernforschungsanlage Jülich GmbH, 5170 Jülich Verfahren zum Aufbau oder zum Abbau von durch chemische Eigenschaften ausgezeichneten, in einer wäßrigen Lösung enthaltenen Stoffen

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3925680A1 (de) * 1989-08-03 1991-02-07 Kruess Gmbh Wissenschaftliche Verfahren zur herstellung vitaler wirkstoff-beladener humanerythrozyten
DE102004054536A1 (de) * 2004-11-06 2006-05-11 Capsulution Nanoscience Ag Multimodal veränderte Zellen als zellulare Darreichungsformen für aktive Substanzen und als diagnostische Zellpartikel

Also Published As

Publication number Publication date
CH632412A5 (de) 1982-10-15
DE2656317A1 (de) 1978-06-22
JPS5396382A (en) 1978-08-23
FR2373290A1 (fr) 1978-07-07
SE7713945L (sv) 1978-06-12
IL53595A (en) 1981-06-29
US4269826A (en) 1981-05-26
FR2373290B1 (cg-RX-API-DMAC7.html) 1983-09-23
GB1560166A (en) 1980-01-30
SE445423B (sv) 1986-06-23

Similar Documents

Publication Publication Date Title
DE2656317C2 (de) Verfahren zur Herstellung einer Suspension von beladenen Erythrocyten
DE2655801C2 (de) Injizierbare Suspension von Membranvesikeln aus Erythrozyten und Verfahren zur Herstellung der Suspension
CH632928A5 (de) Verfahren zur herstellung einer masse von in einer physiologischen loesung suspendierten beladenen zellen.
Caldwell Factors governing movement and distribution of inorganic ions in nerve and muscle.
DE3587639T3 (de) Entwässerte liposome.
DE69126643T2 (de) Methode und Vorrichtung zur Entfernung von Heparin
Katzman Electrolyte distribution in mammalian central nervous system: Are glia high sodium cells?
DE19904785A1 (de) Verfahren zur Herstellung von stabilem Alginatmaterial
DE2538388B2 (de) Verfahren zur Herstellung eines stabilen, nicht-radioaktiven Trägermaterials für mit radioaktiven Elementen markierte Diagnosemittel und seine Verwendung für mit Tc-99m-markierte Diagnosemittel
DE2235681A1 (de) Macroaggregate aus albumin, technetium99m und zinn(ii)-ionen, verfahren zu ihrer herstellung und ihre verwendung als radioindikatoren bei der untersuchung von organen
DE2624815B2 (de) Herstellung einer injizierbaren, stromafreien und von Plasmaproteinen freien Hämoglobinlösung
DE69027686T2 (de) Trennung von verschiedenen zellen
DE2349738A1 (de) Verduennungsmittel
DE69733268T2 (de) Zusammensetzung für die kontrollierte Freisetzung eines Arzneimittels bei der transdermalen Verabreichung
DE2947500A1 (de) Radiojodierte (omega) -phenylfettsaeuren, ihre herstellung und praeparate zur szintigraphischen untersuchung desherzmuskels und der leber
DE69113036T2 (de) Verzögerte arzneistoffabgabe durch topische anwendung bioadhäsiver liposomen.
DE2656333C2 (de) Verfahren zur Herstellung von Liposomen, welche Arzneistoffe enthalten
DE2427659C3 (de) Verfahren zur Herstellung von radioaktiv markierten Erythrozyten
DE3048029A1 (de) Radioassay-methode fuer warmbluetler zur lokalisierung einer entzuendungsreaktion
DE602004008502T2 (de) Herstellungsverfahren einer Zusammensetzung zur Verwendung in einem Elektrotransportabgabesystem
DE2828235C2 (de) Verfahren und Adsorptionsmittel zur Isolierung und Reindarstellung von Enzymen aus einer Roh-Enzym-Lösung
DE3049533A1 (de) Radioassaymethode fuer warmbluetler
DE3784080T2 (de) Antivirales therapeutikum.
Anderson et al. Electrophysiological observations on the digitalis-potassium interaction in canine Purkinje fibers.
DE2124751A1 (de) Verfahren zur Herstellung eines diagnostischen Präparats auf Basis eines mit 99mTc markierten Eisenkomplexes

Legal Events

Date Code Title Description
OAP Request for examination filed
OD Request for examination
D2 Grant after examination
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee